GlassScriptPhysician profile
Colin M Movsowitz
NPI 1508830084
$87,473.81
in general payments reported to CMS, 2019-2025
25 companies · $6,323 in 2025
The $6,323 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $13K · 2021: $13K · 2022: $12K · 2023: $5,791 · 2024: $8,046 · 2025: $6,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,183 · Consulting Fee: $5,988 · Travel and Lodging: $3,490 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,182.93 |
| Consulting Fee | $5,987.50 |
| Travel and Lodging | $3,489.70 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30,285.75 | 2019-2025 | Ingevity+, Watchman Flx, Watchman Access System |
| Impulse Dynamics (USA) INC. | $18,672.12 | 2019-2022 | |
| Biotronik INC. | $12,765.62 | 2019-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Pamira |
| Pfizer INC. | $9,218.83 | 2019-2025 | |
| Abbott Laboratories | $5,749.17 | 2019-2025 | Aveir, Viewmate, Ensite Precision |
| Medtronic, INC. | $4,430.63 | 2021-2025 | Micra, Linq II, Arctic Front Advance |
| Infobionic, INC | $2,981.23 | 2020-2025 | Mome Device, Mome Kardia |
| Janssen Pharmaceuticals, INC | $1,155.80 | 2019-2024 | Xarelto |
| Biosense Webster, INC. | $372.45 | 2019-2024 | Carto 3, Octaray Mapping Catheter, Qdot Micro Catheter |
| Medtronic Vascular, INC. | $294.97 | 2019-2020 | |
| Elutia, INC. | $248.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $189.67 | 2020-2023 | Camzyos |
| Atricure, INC. | $139.45 | 2019 | |
| Zoll Respicardia, INC. | $131.74 | 2019 | |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Labs, Cleerly Ischemia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $121.00 | 2019 | |
| Merck Sharp & Dohme LLC | $119.39 | 2022-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.28 | 2019-2023 | Lifevest |
| Cvrx, INC. | $95.83 | 2023 | Barostim Neo System |
| Medical Device Business Services, INC. | $79.96 | 2024 | Carto 3 |
| Amgen INC. | $69.52 | 2021-2025 | Repatha, Repatha |
| Becton, Dickinson and Company | $54.46 | 2025 | Hemosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.30 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $23.01 | 2024 | |
| Tactile Systems Technology INC | $21.12 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Movsowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.